ProQR Therapeutics N.V

Research ProQR Therapeutics N.V (PRQR) on Bullrun: market cap USD 192.81M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPRQR
• ExchangeNASDAQ
• CountryNetherlands
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 192.81M
• Financial periodQ1 2026
• RevenueUSD 2.03M
• Net income-USD 45.49M
• Free cash flow-USD 49.10M

Valuation Snapshot

latest market cap is USD 192.81M.

About ProQR Therapeutics N.V

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome;

Frequently asked questions

What is ProQR Therapeutics N.V's market cap?

ProQR Therapeutics N.V's market capitalization is USD 192.81M.

What does ProQR Therapeutics N.V do?

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.